Why the study?
Despite the important role of fatty acids in metastasis, the regulation of fatty acid supply in metastatic niches had not been defined.
Does inhibition of endothelial mTORC1 reduce metastatic tumor burden in metastatic disease models?
Does inhibition of endothelial mTORC1 reduce metastatic tumor burden in metastatic disease models?
Transendothelial fatty acid delivery via mTORC1 promotes metastatic outgrowth, and its targeted inhibition reduces tumor burden and improves immune checkpoint responses in preclinical models.
Answers are grounded in this paper and cite their sources.
Endothelial FA transfer may promote metastasis; hypothesis-generating and requires clinical validation before therapeutic targeting.
Metastatic outgrowth in distant microscopic niches requires sufficient nutrients, including fatty acids (FAs), to support tumor growth and to generate an immunosuppressive tumor microenvironment (TME). However, despite the important role of FAs in metastasis, the regulation of FA supply in metastatic niches has not been defined. In this report, we show that tumor endothelium actively promotes outgrowth and restricts antitumor cytolysis by transferring FAs into developing metastatic tumors. We describe a process of transendothelial FA delivery via endosomes that requires mTORC1 activity. Thus, endothelial cell-specific targeted deletion of Raptor (RptorECKO), a unique component of the mTORC1 complex, significantly reduced metastatic tumor burden that was associated with improved markers of T cell cytotoxicity. Low-dose everolimus that selectively inhibited endothelial mTORC1 improves immune checkpoint responses in metastatic disease models. This work reveals the importance of transendothelial nutrient delivery to the TME, highlighting a future target for therapeutic development.
No takes yet. Share an insight, caveat, or question.
Edwards et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: